Strategies for identifying and developing new anticonvulsant drugs
- PMID: 1502014
- DOI: 10.1007/BF01962704
Strategies for identifying and developing new anticonvulsant drugs
Abstract
The identification of new anticonvulsant drugs depends on the use of different animal models of epilepsy. The models should be mechanism-independent, able to screen a large number of compounds, at limited cost and technical expertise. Primary screening models include genetic or reflex models of epilepsy and electrically and chemically induced seizures. Once active compounds have been identified, more advanced mechanistic and seizure-specific models are needed to refine the choice of a lead compound. These can be either in vivo or in vitro models. Models known to interact with specific receptors or the production of the putative neurotransmitters of neural excitability or inhibition are valuable in assessing possible mechanisms of action. In vitro models have evolved as important tools in correlating changes in electrical phenomena and therapeutic spectrum. The use of the hippocampal slice and the cultured neuron permits classification of anticonvulsant activity based on cellular actions of the drug. Interactions by the experimental drugs with specific subcellular fractions of the central nervous system augment information on possible mechanisms of action. The final choice of compounds for development requires synthesizing and comparing all of the pharmacodynamic information with the pharmacokinetic and toxicologic data. In the final analysis, no single animal model of epilepsy known today can assure the development of better drugs for all treatment of the epilepsies.
Similar articles
-
Genetic animal models of epilepsy as a unique resource for the evaluation of anticonvulsant drugs. A review.Methods Find Exp Clin Pharmacol. 1984 Sep;6(9):531-47. Methods Find Exp Clin Pharmacol. 1984. PMID: 6439966 Review.
-
The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. IV. Protective indices.Epilepsy Res. 1991 May-Jun;9(1):1-10. doi: 10.1016/0920-1211(91)90041-d. Epilepsy Res. 1991. PMID: 1884714
-
Profile of SB-204269, a mechanistically novel anticonvulsant drug, in rat models of focal and generalized epileptic seizures.Br J Pharmacol. 1997 Aug;121(8):1679-86. doi: 10.1038/sj.bjp.0701330. Br J Pharmacol. 1997. PMID: 9283703 Free PMC article.
-
Animal Models of Seizures and Epilepsy: Past, Present, and Future Role for the Discovery of Antiseizure Drugs.Neurochem Res. 2017 Jul;42(7):1873-1888. doi: 10.1007/s11064-017-2222-z. Epub 2017 Mar 13. Neurochem Res. 2017. PMID: 28290134 Review.
-
New visions in the pharmacology of anticonvulsion.Eur J Pharmacol. 1998 Jan 19;342(1):1-13. doi: 10.1016/s0014-2999(97)01514-8. Eur J Pharmacol. 1998. PMID: 9544786 Review.
Cited by
-
Psychopharmacological effects and safety of styryl-2-pyrones and dihydrostyryl-2-pyrones-rich fraction from Polygala sabulosa: absence of withdrawal syndrome and tolerance to anxiolytic-like and anticonvulsant effects.J Pharm Pharmacol. 2018 Sep;70(9):1272-1286. doi: 10.1111/jphp.12960. Epub 2018 Jun 28. J Pharm Pharmacol. 2018. PMID: 29956326 Free PMC article.
-
Anticonvulsant and anxiolytic-like effects of compounds isolated from Polygala sabulosa (Polygalaceae) in rodents: in vitro and in vivo interactions with benzodiazepine binding sites.Psychopharmacology (Berl). 2008 Apr;197(3):351-60. doi: 10.1007/s00213-007-1037-z. Epub 2007 Dec 22. Psychopharmacology (Berl). 2008. PMID: 18157522
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources
Medical